Description

Mozavaptan

Mozavaptan is a high-purity, selective vasopressin V2 receptor antagonist used in pharmaceutical formulations for the treatment of hyponatremia, particularly in patients with the syndrome of inappropriate antidiuretic hormone secretion (SIADH). By blocking V2 receptors in the renal collecting ducts, it promotes aquaresis and increases serum sodium levels without significant loss of electrolytes. Mozavaptan
• Is a pharmaceutical-grade vasopressin V2 receptor antagonist
• Is used in oral tablets or capsule formulations for hyponatremia management
• Promotes aquaresis, increasing serum sodium in patients with SIADH
• Is suitable for chronic and acute therapeutic use under medical supervision
• Is manufactured under Good Manufacturing Practice (GMP) certified conditions
• Is supplied with complete regulatory documentation including Certificate of Analysis (CoA) and technical data
Mozavaptan is chemically designated as N-[4-(5-Chloro-2-methoxybenzamido)phenyl]-2-methylbenzamide. It appears as a white to off-white crystalline powder, with low water solubility and stability suitable for solid oral dosage formulation.
In pharmaceutical applications, Mozavaptan is used in:
• Oral tablets and capsules for the treatment of hyponatremia in SIADH
• Combination therapies addressing electrolyte imbalance and renal function
• Clinical research and trials for aquaretic therapies
• Compounded formulations requiring precise dosing and bioavailability
• Development of controlled-release or fixed-dose oral dosage forms
Mozavaptan selectively inhibits vasopressin V2 receptors, leading to increased free water excretion and correction of serum sodium levels without substantial loss of potassium or other electrolytes. Its pharmacokinetics allow predictable dosing in clinical practice.
CarboMer supplies Mozavaptan with control over assay, particle size, polymorphic form, residual solvents, and microbial purity. Material is suitable for regulated pharmaceutical development and oral dosage formulation.
The material is packaged in sealed, moisture-resistant, tamper-evident containers. Available in laboratory, pilot, and commercial-scale volumes. Minimum order quantities (MOQ), lead times, and documentation including CoA and SDS are provided upon request.
Each batch is tested for identity (IR, HPLC), assay, residual solvents, polymorphic stability, and microbial limits. Certificates of Analysis (CoA), Safety Data Sheets (SDS), and full traceability documentation accompany every shipment.
As with all CarboMer cardiovascular and renal APIs, Mozavaptan is supported by formulation guidance, regulatory expertise, and reliable global supply to ensure safe, effective, and compliant pharmaceutical products.